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Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/
relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the
development of new therapies. Here, we utilize dynamic BH3 profiling (DBP), a functional predictive biomarker that
measures net changes in mitochondrial apoptotic signaling, to identify anti-apoptotic adaptations upon treatment. We
employ this information to guide the use of BH3 mimetics to specifically inhibit BCL-2 pro-survival proteins, defeat
resistance and avoid relapse. Indeed, we found that BH3 mimetics that selectively target anti-apoptotic BCL-xL and
MCL-1, synergistically enhance the effect of clinically used chemotherapeutic agents vincristine and doxorubicin in
RMS cells. We validated this strategy in vivo using a RMS patient-derived xenograft model and observed a reduction in
tumor growth with a tendency to stabilization with the sequential combination of vincristine and the MCL-1 inhibitor
S63845. We identified the molecular mechanism by which RMS cells acquire resistance to vincristine: an enhanced
binding of BID and BAK to MCL-1 after drug exposure, which is suppressed by subsequently adding S63845. Our
findings validate the use of DBP as a functional assay to predict treatment effectiveness in RMS and provide a rationale
for combining BH3 mimetics with chemotherapeutic agents to avoid tumor resistance, improve treatment efficiency,
and decrease undesired secondary effects.
Introduction
Rhabdomyosarcoma (RMS) is a highly malignant cancer
that, despite being relatively rare, is the most frequent
soft-tissue sarcoma in children, accounting for 5% of all
pediatric tumors1. RMS tumors are highly aggressive and
typically develop from skeletal muscle cells, arising in a
variety of anatomic sites in the body2,3. There is a slightly
higher prevalence of this disease in males than in females,
and it is often associated with genetic disorders, such as
Li–Fraumeni familiar cancer syndrome and
neurofibromatosis type 12. Based on histologic criteria,
RMS tumors are subdivided into two main groups,
embryonal (ERMS) and alveolar (ARMS). ERMS account
for 60% of all RMS, affecting children under the age of 10,
especially around the head and neck regions2,3. ARMS
represent ~20% of all RMS, occurring mostly in adoles-
cents and frequently localized in the limbs3,4. The current
treatment strategies for RMS include chemotherapy,
radiation, and surgery4. Despite treatment improvement
for patients with low-risk and intermediate-risk disease,
the survival rates for high-risk patients have not advanced
in the past decades4. Furthermore, the derived toxicities
from current treatments and the lack of biomarkers5,
highlight the need for new therapies to enhance RMS
clinical outcomes.
© The Author(s) 2020
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Joan Montero (jmontero@ibecbarcelona.eu)
1Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science
and Technology (BIST), 08028 Barcelona, Spain
2Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de
Déu, 08950 Esplugues de Llobregat, Spain
Full list of author information is available at the end of the article
Edited by C. Munoz-Pinedo


































Therapy causes the death of cancer cells mostly by
apoptosis, a process controlled by the BCL-2 family of
proteins6. Its members are classified based on their
structure, BCL-2 homology (BH) domains, and their
function6,7. In brief, the anti-apoptotic proteins (BCL-2,
BCL-xL MCL-1, and others) present up to four BH
domains (BH1–BH4) and bind to pro-apoptotic proteins.
The pro-apoptotic effector proteins BAX and BAK also
contain several BH domains and have the capacity to
oligomerize and form pores in the mitochondrial outer
membrane. Their function is induced by activator pro-
teins possessing a unique BH3 domain, such as BIM, BID
(mostly through the truncated form, tBID), or PUMA.
There is a fourth group of BCL-2 family proteins - the
so-called sensitizers - also presenting a unique BH3
domain that cannot directly activate effectors, but can
inhibit anti-apoptotic members. Sensitizers include
BAD, HRK, BIK, NOXA, and BMF - among others - and
exert a pro-apoptotic effect by competing for specific
binding to anti-apoptotic BCL-2 family proteins7.
Overall, these proteins regulate mitochondrial outer
membrane permeabilization (MOMP) and the release of
cytochrome c (and other proteins) that represents the
point of no return for apoptotic cell death. Importantly,
MOMP can be prevented by anti-apoptotic proteins
through direct binding to BAX and BAK or activator
BH3-only proteins7.
Evasion of apoptosis is a hallmark of human cancers and
can be often explained by the increased expression of anti-
apoptotic proteins8,9. In fact, high levels of BCL-2 and
MCL-1 have been reported in RMS patients as a pro-
survival mechanism10,11. Therefore, targeting anti-
apoptotic proteins represents a promising therapeutic
approach to treat high-risk or relapsed RMS patients9,12.
In this regard, BH3 mimetics - a novel class of ther-
apeutics that mimic the action of sensitizer BH3-only
proteins and selectively inhibit anti-apoptotic BCL-2
family members7 - could be used to overcome apoptotic
resistance. There is an increasing interest in BH3
mimetics due to their therapeutic potential alone or in
combination with other treatments, but the main ques-
tions that clinicians must face are when and how to use
BH3 mimetics as anti-cancer therapies in the clinic7. On
this subject, the functional assay dynamic BH3 profiling
(DBP) can determine in <24 h how effective a treatment
will be to engage apoptosis13. This technology uses syn-
thetic BH3 peptides derived from BCL-2 family proteins
to measure how close cells are to the apoptotic threshold
(or how primed for death). DBP has been successfully
used to predict - from days to weeks in advance - treat-
ment effectiveness in cell lines, murine models, and
patient samples13–17. In addition to overall susceptibility
to apoptosis, DBP can identify the selective dependence of
cancer cells on anti-apoptotic proteins, and guide the use
of BH3 mimetics to overcome therapy-induced
resistance7.
Several publications by Fulda and colleagues elegantly
demonstrate BH3 mimetics’ therapeutic potential to treat
RMS12,18–20, although sequential combination of anti-
cancer agents with BH3 mimetics has not been fully
assessed. Here, we report a new strategy that utilizes low-
dose combinations of chemotherapeutic agents with BH3
mimetics to increase the efficacy of current treatments,
while decreasing therapy-induced toxicity21 and anti-
apoptotic protection.
Materials and methods
Cell lines and treatments
RMS cell lines (CW9019, RD, and RH4) were kindly
provided by Dr. Oscar Martínez-Tirado and Dr. Cristina
Muñoz-Pinedo from the Bellvitge Biomedical Research
Institute (IDIBELL). C2C12 cells were purchased at
ATCC (ATCC® CRL-1772™, ATCC, Manassas, VI, USA).
Human skeletal muscle myoblasts (HSMM) were pur-
chased at Lonza (CC-2580, Lonza, Basel, Switzerland).
RMS cell lines were cultured in RPMI 1640 medium
(31870, Thermo Fisher, Gibco, Paisley, Scotland) supple-
mented with 10% heat-inactivated fetal bovine serum
(10270, Thermo Fisher, Gibco), 1% of L-glutamine (25030,
Thermo Fisher, Gibco), and 1% of penicillin and strep-
tomycin (15140, Thermo Fisher, Gibco). C2C12 cells were
cultured in DMEM high glucose medium (41965, Thermo
Fisher, Gibco) supplemented with 10% heat-inactivated
fetal bovine serum (10270, Thermo Fisher, Gibco) and 1%
of penicillin and streptomycin (15140, Thermo Fisher,
Gibco). HSMM cells were cultured in SKBM-2 medium
(CC-3246, Lonza) supplemented with its specific Single-
QuotsTM and growth factors (CC-3244, Lonza). All cells
were tested for mycoplasma and maintained at 37 °C in a
humidified atmosphere of 5% CO2. Drug treatments were
performed directly in the culture media at the doses and
time points indicated in every single experiment. All drugs
were purchased at Selleckchem (Munich, Germany).
Dynamic BH3 profiling
DBP experiments were performed as previously
described22,23. In brief, 3 × 104 cells/well in a 96-well plate
were used for cell lines. 25 μL of BIM BH3 peptide (final
concentration of 0.01, 0.03, 0.1, 0.3, 1, 3, and 10 μM),
25 μL of BAD BH3 peptide (final concentration of 10 μM),
25 μL of HRK BH3 peptide (final concentration of
100 μM), and 25 μL of MS1 BH3 peptide24 (final con-
centration of 10 μM) in MEB (150mM mannitol, 10 mM
hepes–KOH pH 7.5, 150mM KCl, 1 mM EGTA, 1 mM
EDTA, 0.1% BSA, 5 mM succinate) with 0.002% digitonin
were deposited per well in a 96-well plate (3795, Corning,
Madrid, Spain). Single cell suspensions were stained with
the viability marker Zombie Violet (423113, BioLegend,
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Koblenz, Germany) and then washed with PBS and
resuspended in MEB in a final volume of 25 μL. Cell
suspensions were incubated with the peptides for 1 h
following fixation with formaldehyde and staining with
cytochrome c antibody (Alexa Fluor® 647 anti-
Cytochrome c—6H2.B4, 612310, BioLegend). Individual
DBP analyses were performed using triplicates for DMSO,
alamethecin (BML-A150-0005, Enzo Life Sciences, Lor-
rach, Germany), the different BIM BH3 concentrations
used, BAD, HRK, and MS1 BH3 peptides. The expressed
values stand for the average of three different readings
performed with a high-throughput flow cytometry SONY
instrument (SONY SA3800, Surrey, UK). % priming
stands for the % of cytochrome c release obtained from
different BH3 peptides, and Δ% priming represents the
difference between treated cells minus non-treated cells
for a given peptide.
Cell death analysis
Cells were stained with fluorescent conjugates of
Annexin V (FITC Annexin V, 640906 or Alexa Fluor® 647
Annexin V, 640912, BioLegend) and propidium iodide
(PI) (1056, BioVision, Milpitas, CA, USA) or DAPI
(62248, Thermo Fisher) and analyzed on a flow cytometry
Gallios instrument (Beckman Coulter, Nyon, Switzer-
land). Viable cells are Annexin V negative and PI or DAPI
negative, and cell death is expressed as 100%-viable cells.
Protein extraction and quantification
Proteins were extracted by lysing the cells for 30 min at
4 °C using RIPA buffer (150 mM NaCl, 5 mM EDTA,
50mM Tris–HCl pH= 8, 1% Triton X-100, 0.1% SDS,
EDTA-free Protease Inhibitor Cocktail (4693159001
Roche, Mannkin, Germany)) followed by a centrifugation
at 16,100 × g for 10 min. The supernatant was stored at
−20 °C for protein quantification performed using Pier-
ceTM BCA Protein Assay Kit (23227, Thermo Fisher).
Immunoprecipitation
Cells were lysed in Immunoprecipitation buffer
(150 mM NaCl, 10 mM Hepes, 2 mM EDTA, 1% Triton,
1.5 mM MgCl2, 10% glycerol, and EDTA-free Protease
Inhibitor Cocktail (4693159001 Roche)) and centrifuged
at 14,000 × g, 15 min at 4 °C. The resulting supernatants
were incubated with magnetic beads (161-4021, Bio-Rad,
Madrid, Spain) conjugated to 5 μg of rabbit anti-MCL-1
antibody (CST94296, Cell Signaling, Leiden, The Neth-
erlands) or 5 μg of rabbit IgG antibody (CST2729, Cell
Signaling) at 4 °C overnight. A fraction of the supernatant
(30 μL) was removed and mixed with half volume of 4×
SDS–PAGE sample buffer, heated at 96 °C for 5 min and
stored at −80 °C as cell lysate fractions. After magneti-
zation, a part of the supernatant was mixed with half
volume of 4× SDS–PAGE sample buffer, heated at 96 °C
for 5 min and stored at −80 °C as unbound fractions. The
rest of the supernatant was discarded. The resulting pellet
was washed and mixed with 40 μL 4× SDS–PAGE sample
buffer and heated for 10min at 70 °C to allow the dis-
sociation between the purified target proteins and the
beads–antibody complex. The sample was magnetized
and the supernatant was collected and stored at −80 °C as
IP fractions for further immunoblotting (Western blot)
analyses.
Immunoblotting
Proteins were separated by SDS–PAGE (Mini-Protean
TGX Precast Gel 12%, 456-1045, Bio-Rad) and transferred
to PVDF membranes (10600023, Amersham Hybond,
Pittsburgh, PA, USA). Membranes were blocked with dry
milk dissolved in Tris buffer saline with 1% Tween 20
(TBST) for 1 h and probed overnight at 4 °C with the
primary antibodies of interest directed against: rabbit anti-
BCL-2 (CST4223, Cell Signaling), rabbit anti-BCL-xL
(CST2764, Cell Signaling), rabbit anti-MCL-1 (CST5453,
Cell Signaling), rabbit anti-BIM (CST2933, Cell Signal-
ing), rabbit anti-BID (CST2002, Cell Signaling), rabbit
anti-BAK (CST12105, Cell Signaling), rabbit anti-BAX
(CST2772, Cell Signaling), rabbit anti-Actin (CST4970,
Cell Signaling) followed by anti-rabbit IgG HRP-linked
secondary antibody (CST7074, Cell Signaling) in 3% BSA
in TBST for 1 h at room temperature. Immunoblots were
developed using Clarity ECL Western substrate (1705060,
Bio-Rad). When necessary, immunoblots were stripped in
0.1M glycine pH 2.5, 2% SDS for 40min and washed in
TBS. Bands were visualized with LAS4000 imager (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden) and Ima-
geJ was then used to measure the integrated optical
density of bands.
Development of RMS orthoxenograft mouse model
Six-week-old male athymic nu/nu mice (Envigo, Bar-
celona, Spain) weighing 18–22 g were used in this study.
Animals were housed in a sterile environment, in cages
with autoclaved bedding, food, and water. Mice were
maintained on a daily 12 h light, 12 h dark cycle. The
Institutional Ethics Committees approved the study pro-
tocol, and the animal experimental design was approved
by the IDIBELL animal facility committee (AAALAC
Unit1155). All experiments were performed in accordance
with the guideline for Ethical Conduct in the Care and
Use of Animals as stated in The International Guiding
Principles for Biomedical Research Involving Animals,
developed by the Council for International Organizations
of Medical Sciences.
An embryonal rhabdomyosarcoma (ERMS) orthoxeno-
graft was generated from a small biopsy of a metastatic
case taken at diagnostic from the primary tumor located
in the child gluteus. The patient gave written consent to
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participate in the study. The primary tumor did not
receive radiotherapy or chemotherapy prior to surgery.
Under isoflurane anesthesia, a subcutaneous pocket was
made with surgical scissors. Then, a small incision was
made in the muscle and the tumor was fixed with syn-
thetic monofilament, non-absorbable polypropylene
suture (Prolene 7.0) to the muscle of the upper thigh
(orthotopic implantation). After implantation, tumor
formation was checked weekly by palpation. Orthotopic
tumor (named RMSX1) became apparent 1–3 months
after engraftment. Once orthotopic tumors had reached a
volume of around 1500 mm3, mice were sacrificed and
tumors were passed to another three animals in order to
obtain a sufficient quantity of tumor material. After each
passage tumors were frozen, paraffin-embedded, and
cryopreserved in (10% DMSO+ 90% non-inactivated fetal
bovine serum (10270, Thermo Fisher, Gibco)) to provide a
source of viable tissue for future experiments.
Drug treatment in ERMS RMSX1 orthoxenograft tumor
model
The orthoxenograft procedure was approved by the
campus Animal Ethics Committee and complied with
Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC) pro-
cedures. A mouse harboring RMSX1 tumor - orthotopi-
cally growing, at passage#2 - was sacrificed, tumors were
harvested and cut into small fragments 4 × 4 mm3, and the
tumor fragments were grafted in 20 young mice. When
tumors reached a homogeneous size (1200–1500mm3),
mice were randomly allocated into the different treatment
groups (n= 4/group): (i) Placebo; (ii) ABT-199 (100 mg/
kg); (iii) vincristine (1 mg/kg); (iv) S63845 (20mg/kg); and
(v) combined vincristine (1 mg/kg) plus S63845 (20 mg/
kg). Vincristine was intravenously administrated via tail
vein injection (i.v.) once per week for 3 consecutive weeks
(days 0, 7, and 14). ABT-199 was daily administered (q.d.)
by oral gavage (p.o.) for 21 days and S63845 was i.v.
administered 3 consecutive days per week for 2 weeks. All
the animals/groups were sacrificed at day 21. To minimize
in combined treatments the risk of developing drug-
induced toxicity, drugs were administered spaced in time.
Vincristine was administered first and S63845 2 h later.
Vincristine from Eli Lilly (1 mg/ml) was purchased at the
hospital pharmacy of the Catalan Institute of Oncology
(ICO) and diluted in saline before use. ABT-199 and
S63845 were purchased at Selleckchem. ABT-199 was
diluted in 10% Ethanol/30% PEG 400/60% Phosal 50 PG
(v/v/v), while S63845 was diluted in 10% DMSO/40% PEG
300/5% Tween 80/saline. After treatment initiation,
tumors were measured using a caliper every 2–3 days and
tumor volume was calculated using the formula v= (w² ×
l)/2, where l is the longest diameter and w the width. At
the moment of sacrifice, tumor was dissected out and
weighed. Representative fragments were either frozen in
nitrogen or fixed and then processed for paraffin
embedding.
PDX cell isolation
Primary tumors from PDX animals were exposed to an
enzymatic digestion after mechanical disaggregation in
2.5 mL of DMEM media with 125 units of DNAse I
(DN25, Sigma-Aldrich, Buchs, Switzerland), 100 units of
Hyaluronidase (H3506, Sigma-Aldrich), and 300 units of
collagenase IV (17104-019, Thermo Fisher, Gibco). The
tissue suspension was processed using gentleMACS Dis-
sociator (Miltenyl Biotec, Madrid, Spain) using the
hTUMOR 1 program. The suspension was incubated at
37 °C for 30min with constant agitation. Then, the pro-
gram hTUMOR 1 was ran again and repeated the 30 min
incubation. We filtered the suspension with a 70 micron
filter into a 50mL conical and cells were spun down at
500 × g for 5 min. To lyse the residual red blood cells,
100 μL of ice cold water was added for 15 s and then
diluted to 50mL with PBS, then cells were spun down
again. Cells were finally resuspended in RPMI media,
counted by trypan blue exclusion and plated in a 12-well
plate, 3 × 104 cells/well and treated with DMSO or vin-
cristine 1 nM. After a 16 h incubation at 37 °C in a
humidified atmosphere of 5% CO2, DBP analyses were
performed.
Statistical analysis
Statistical significance of the results was analyzed using
Student’s t-tail test. *p < 0.05 and **p < 0.01 were con-
sidered significant. SEM stands for Standard Error of the
Mean. For ROC curve analysis, cell lines were considered
responsive to treatment when Δ% cell death > 20%. Drug
synergies were established based on the Bliss Independent
model as previously described25. Combinatorial index (CI)
was calculated CI= ((DA+DB)− (DA*DB))/DAB, where D
represents cell death of compound A or B or the com-
bination of both. Only the combination of drugs with a CI
< 1 were considered synergies. GraphPad Prism8 was used
to generate the graphs and to perform the statistical
analyses.
Results
Novel chemotherapy combinations with BH3 mimetics to
increase RMS cytotoxicity
Chemotherapeutic agents are commonly used in clinical
protocols for RMS treatment4. However, they negatively
impact patients with short-term and long-term therapy
toxicities26, and often treatment resistance is acquired by
cancer cells27. Therefore, we focused on reducing che-
motherapeutic dosage to decrease therapy-associated
undesired effects. First, we used DBP to analyze the
increase in priming after incubation with four standard of
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care RMS chemotherapeutic agents: the microtubule-
destabilizing agent vincristine, the alkylating molecule
cyclophosphamide, the anthracycline doxorubicin, and
the topoisomerase inhibitor etoposide28. We performed
DBP on three different RMS cell lines to account for the
disease heterogeneity: two ARMS cell lines (CW9019 and
RH4) and an ERMS cell line (RD). In CW9019 cells, we
observed an increase in apoptotic priming upon treatment
(Δ% priming) after a short incubation with vincristine and
doxorubicin, but not with cyclophosphamide or etoposide
(Fig. 1a). Using Annexin V and PI or DAPI staining, we
analyzed by flow cytometry cell death after 96 h of
exposure to the same chemotherapeutic agents as a proof
of principle to evaluate the correlation between DBP
predictions and later cell death. We observed high levels
of cell death (between 40% and 80%) after vincristine
treatment and even nearly complete elimination of cells
with doxorubicin, but no effect with cyclophosphamide or
etoposide, confirming DBP predictions (Fig. 1b). Similar
results were obtained in the other two RMS cell lines, RD
and RH4 (Fig. 1a, b). When we statistically compared Δ%
priming and % cell death in all three cell lines, we
observed a significant correlation (Fig. 1c). To further
determine how good DBP is as a binary predictor for
RMS, we performed a Receiver Operating Characteristic
(ROC) curve analysis29. We observed that the area under
the curve (AUC) for our experiments was 0.81 (Fig. 1d),
indicating that DBP presents a good predictive capacity
for chemotherapy cytotoxicity in the RMS cell lines tested.
As mentioned above, one of the hallmarks of cancer is
treatment adaptation and resistance to anti-cancer
drugs27. This resistance can be acquired by different
Fig. 1 Dynamic BH3 profiling predicts chemotherapy sensitivity in different RMS cell lines. a Results from the DBP assay after 36 h incubation
with the treatments in CW9019, RD, and RH4 cells. Results expressed as Δ% priming represents the increase in priming compared to control cells. b
Cell death results from Annexin V and propidium iodide/DAPI staining FACS analyses after 96 h incubation with the chemotherapeutic agents in
CW9019, RD, and RH4 cells. c Correlation between Δ% priming at 36 h and % cell death at 96 h. d Receiver operating characteristic curve analysis.
Values indicate mean values ± SEM from at least three independent experiments. **p < 0.01 and *p < 0.05.
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mechanisms such as drug target alterations (mutations),
drug export transporters’ gain, increased DNA damage
repair, altered proliferation and - as we further investi-
gated - through anti-apoptotic BCL-2 proteins30. Using
specific synthetic BH3 peptides, that mimic sensitizer
BCL-2 family proteins, with DBP we can identify which is
the anti-apoptotic protein that cancer cells rely on to
acquire resistance to a given treatment7. In this regard, we
can precisely evaluate the contribution of three main pro-
survival BCL-2 family members: BCL-2/BCL-xL depen-
dence with the BAD BH3 peptide, BCL-xL dependence
with the HRK BH3 peptide, and MCL-1 dependence with
the MS1 BH3 peptide7,22–24,31. First, we observed that
CW9019 cells present low initial BCL-2, BCL-xL, and
MCL-1 dependence (Fig. 2a) based on the basal priming
observed in control cells6. However, we identified that
these cells experimented an increase in % priming,
referred as Δ% priming with BAD, HRK, and MS1 BH3
peptides upon vincristine treatment (Fig. 2a), pointing to
BCL-xL and MCL-1 mediated pro-survival adaptation. In
consequence, we decided to pharmacologically exploit
this anti-apoptotic dependence utilizing two new selective
BH3 mimetics: S63845 (MCL-1 inhibitor)32 and A-
1331852 (A-133) (BCL-xL inhibitor)33 and test their
cytotoxic effect in combination with vincristine. We
observed that sequentially adding S63845 or A-1331852
after 36 h of exposure to vincristine significantly increased
cell death at 96 h compared to single agents (Fig. 2b). In
fact, the combination index (CI) calculations25 indicated
that S63845 addition to vincristine is synergistic (CI=
0.916) while A-1331852 is additive (CI= 1.028). Obtain-
ing synergy between two agents is an important goal to
decrease treatment toxicity and to avoid undesired side
effects associated with high doses of chemotherapy, a
constant challenge for pediatric cancer25. We repeated
these experiments with another RMS standard che-
motherapeutic agent, doxorubicin, and we observed an
increase in Δ% priming with DBP (Fig. 1a) and a high
percentage of cell death with Annexin V and DAPI
staining (Fig. 1b). Like vincristine, we could detect an
increase in priming with BAD, HRK, and MS1 BH3
peptides in CW9019 cells (Supplementary Fig. 1a) indi-
cating that cancer cells also acquired resistance to dox-
orubicin treatment through BCL-xL and MCL-1.
Doxorubicin is already a potent chemotherapeutic drug as
a single agent and exerts an extensive cytotoxicity after
96 h (Fig. 1b), but also causes cardiotoxicity in the clinic21.
Therefore, we sought to reduce doxorubicin dosing by
exploring synergistic sequences with the anti-apoptotic
inhibitors A-1331852 and S63845. Hereof, doxorubicin
combined with both BH3 mimetics was highly cytotoxic
at 96 h for RMS cells, even when reducing ten-fold its
concentration (Supplementary Fig. 1B). Both combina-
tions of doxorubicin with S63845 or A-1331852 were
synergistic as we observed a CI= 0.522 and CI= 0.836,
respectively. These combinations were effective in RMS
Fig. 2 Dynamic BH3 profiling predicts synergistic combinations with vincristine and BH3 mimetics in the CW9019 cell line. a Results from
the contribution of each anti-apoptotic protein: BCL-2/BCL-xL dependence BAD peptide; BCL-xL dependence HRK peptide; and MCL-1 dependence
MS1 peptide in acquiring resistance to vincristine 1 nM treatment. Results expressed as Δ% priming represents the increase in priming compared to
control cells. HRK and MS1 BH3 peptides showed a significant increase, indicating BCL-xL and MCL-1 adaptation, respectively. b Cell death from
Annexin V and propidium iodide staining FACS analyses after 96 h incubation of CW9019 cells with single agents or the combination of vincristine
(1 nM) with the corresponding BH3 mimetics S63845 (1 µM) and A-1331852 (0.1 µM) for 96 h. Values indicate mean values ± SEM from at least three
independent experiment. **p < 0.01, *p < 0.05 compared to single agents and # indicates CI < 1.
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cell lines but we did not observe any cytotoxic effect in
non-tumoral myoblast cells (Supplementary Fig. 2), indi-
cating specific toxicity of these treatments for malignant
cells. Additionally, we analyzed different anti-apoptotic
BCL-2 family proteins expression to determine molecular
fluctuations after vincristine and doxorubicin treatments.
Surprisingly, we found that upon vincristine treatment
there were no significant changes in the anti-apoptotic
proteins MCL-1, BCL-xL, or BCL-2 expression, indicating
that cancer cells’ adaptation to this therapy relies on dif-
ferent mechanisms other than increased expression of
these proteins (Fig. 3a). On the other hand, doxorubicin
treatment led to a different adaptation: marked decline in
MCL-1 and BCL-xL levels, an increase in BCL-2, BAD,
and BIM expression and a decrease in the pro-apoptotic
protein BID (Supplementary Fig. 3). From this first set of
experiments we conclude that we can increase che-
motherapeutic agents’ efficacy by rationally combining
them with specific BH3 mimetics. Despite not being the
most synergistic combination observed, but taking into
account the cardiotoxicity caused by doxorubicin21, we
postulated the sequential treatment of vincristine and
S63845 as the most promising and effective therapy for
RMS, and we further studied it (Fig. 2b).
Vincristine promotes MCL-1-mediated resistance
To better understand the molecular adaptation by
which cells acquire resistance to vincristine and why its
combination with S63845 is highly effective in vitro, we
analyzed MCL-1 interactions with other BCL-2 family
proteins by performing immunoprecipitation assays. First,
we found that there were no significant expression
changes in effectors and activator BCL-2 family proteins
in cell lysates when exposed to vincristine or its sequential
combination with S63845 (Fig. 3b). Using CW9019 cells
we observed a significant MCL-1 decrease in the flow
through fraction despite similar MCL-1 levels in initial
cell lysates (Fig. 4a), and a good detection in the pulled
Fig. 3 Vincristine treatment subtly affects BCL-2 family proteins. a Anti-apoptotic protein levels analysis by Western blot from control CW9019
cells and after the treatment with 1 nM vincristine for 36 h. b Effector and activator BCL-2 family protein levels analysis by Western blot from control
CW9019 cells, after vincristine (1 nM) and the sequential combination with S63845 (1 µM) for 36 h. Quantification of the optical density of each
protein and normalized with actin. Results expressed as fold increase represents the increase in optical density compared to control cells. Values
indicate mean values ± SEM from at least three independent experiments.
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down samples (Fig. 4c, d). We assessed MCL-1 binding
with activator proteins BIM and BID after vincristine
treatment. As previously described, MCL-1 can bind to
the truncated form of BID (tBID), prevent BAX and BAK
activation, MOMP, and apoptosis34. Indeed, we could
observe an increase in binding between MCL-1 and tBID
Fig. 4 Vincristine induces resistance in RMS cells through BID and BAK inhibition by MCL-1. a Left panel: Western blot results of the unbound
fraction after MCL-1 immunoprecipitation. Right panel: MCL-1 levels in the initial cell lysates. High efficiency of MCL-1 immunoprecipitation
compared to Rabbit IgG control antibody. b Western blot results of the co-immunoprecipitation between MCL-1 and tBID in control conditions and
after 1 nM vincristine treatment for 36 h. Results showed a significant increase in tBID and MCL-1 binding after vincristine treatment. c Western blot
results of the co-immunoprecipitation between MCL-1 and BAK in control conditions, after 1 nM vincristine treatment and after the sequential
combination of 1 nM vincristine and 1 µM S63845 for 36 h. Results showed a significant increase in BAK and MCL-1 binding after vincristine treatment,
which was decreased below control levels after the addition of S63845. Values indicate mean values ± SEM from at least three independent
experiments. **p < 0.01, *p < 0.05.
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after vincristine treatment (Fig. 4b) but not with BIM
(Supplementary Fig. 4A). When we studied BCL-2 family
effector proteins we observed that vincristine treatment
caused a significant increase in MCL-1 binding with BAK
(Fig. 4c) but not with BAX (Supplementary Fig. 4B). These
observations correlate with previous reports showing
tBID preferential activation of BAK over BAX35, and
MCL-1 sequestration of BAK as a resistance mechanism
to anti-cancer treatments36,37. Importantly, this enhanced
binding could be reversed by S63845 addition after vin-
cristine treatment (Fig. 4c), decreasing MCL-1:BAK
binding below control levels and recovering CW9019
cells’ apoptotic function. Vincristine treatment increases
priming and pro-apoptotic proteins tBID and BAK
binding to MCL1, which can be released by S63845. These
findings demonstrate why the sequential combination of
vincristine and S63845 is effective against RMS.
Effective therapeutic combination in vivo of vincristine
with the MCL-1 inhibitor S63845
Patient-derived xenografts (PDXs) are advantageous in
pre-clinical research as they recapitulate patients’ ther-
apeutic response26. After identifying different effective
combinations in vitro, we analyzed tumors from RMS
PDX models. We disaggregated the tumors to obtain a
single-cell suspension and performed DBP analyses to
evaluate different therapies’ effectiveness and possible
anti-apoptotic adaptations. We focused on chemother-
apeutic agents, particularly on vincristine as it is used in
the clinic to treat RMS and because we already generated
promising preliminary results in vitro in combination
with S63845 (Fig. 1). We analyzed an ERMS orthoxeno-
graft generated from a small biopsy from the primary
tumor located in the gluteus of a metastatic patient, that
we named RMSX1. We detected an increase in Δ%
priming after incubating tumor cells with vincristine (Fig.
5a), but not with cyclophosphamide or etoposide (Sup-
plementary Fig. 5A), similarly to what we observed in cell
lines (Fig. 1). Moreover, we identified by DBP an anti-
apoptotic adaptation to vincristine mediated by MCL-1
(Fig. 5b) that could diminish its efficacy, as previously
observed in vitro (Fig. 2). RMSX1 in vivo single agent
treatment with vincristine or the MCL-1 inhibitor S63845
merely delayed tumor growth after 21 days (Fig. 5c).
Surprisingly, we detected that the sequential combination
of vincristine followed by S63845 was significantly more
effective than single agents and promoted tumor reduc-
tion in vivo (Fig. 5c and Supplementary Fig. 5C). More-
over, we could also observe a significant increase in Δ%
priming after incubating tumor cells with targeted agents,
such as S63845, ABT-199, and SP2509 (Supplementary
Fig. 5A) and we also identified possible anti-apoptotic
adaptations to those treatments by BCL-xL and MCL-1
(Supplementary Fig. 5B) that we will further explore.
Overall, these results demonstrate DBP’s efficacy to
design more effective therapeutic strategies to overcome
anti-apoptotic resistance and avoid cancer progression
using BH3 mimetics.
Discussion
There is an urgent medical need to find more effective
and less toxic treatments for RMS patients, since recur-
rent malignancies present poor prognosis and the overall
survival after relapse is very low31. There is a growing
evidence that the BCL-2 family of proteins (particularly
the anti-apoptotic members) may mediate drug resistance
in cancer cells causing disease progression in patients7,8.
Therefore, it is key to predict these acquired pro-survival
mechanisms and overcome them with anti-apoptotic
inhibitors like BH3 mimetics. As mentioned above,
DBP, beyond measuring a given treatment effectiveness to
engage apoptosis, can also detect anti-apoptotic adapta-
tions derived from therapy that promote cancer survival13,
and guide the use of BH3 mimetics to avoid resistance.
Anti-apoptotic inhibitors such as A-1331852 (BCL-xL
selective), ABT-199 (BCL-2 selective), S63845 (MCL-1
selective) among others that are now evaluated in the
clinic, can be used as single agents or especially in com-
bination with other therapies to enhance cancer elim-
ination7. In particular, highly potent and selective MCL-1
inhibitors such as S64315 (also named MIK665, similar to
S63845)32, AZD-599138, and AMG-17639, are currently
explored in clinical trials and hold great promise for
cancer treatment. Therefore, in this study we aimed to
investigate the use of BH3 mimetics to boost RMS sen-
sitivity to current chemotherapy.
At present, radiotherapy, surgery, and chemotherapy
are the standard of care for RMS treatment. Regarding the
latter, a three-drug combination is currently utilized:
vincristine, actinomycin D, and cyclophosphamide (VAC).
This regimen has become the basis for RMS therapy with
the incorporation of other agents, such as etoposide,
doxorubicin, ifosfamide, cisplatin, and others for inter-
mediate risk patients, with scarce clinical outcome
improvement40. However, secondary effects derived from
chemotherapy administration in children are severe and
may include infertility, cardiomyopathy, or the appear-
ance of secondary neoplasia40. One explanation for these
unbearable therapy-associated pediatric toxicities relies
on differential apoptotic priming between young and
adult tissues21. Traditional chemotherapy has reached an
efficacy plateau in RMS, making development of new
therapies that increase efficacy while decreasing toxicity a
clear unmet need. Thus, we sought to identify possible
mechanisms of resistance to chemotherapeutic agents,
such as vincristine or doxorubicin that could explain their
limited clinical efficacy by analyzing anti-apoptotic
changes with DBP (Fig. 2 and Supplementary Fig. 1).
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Indeed, we identified anti-apoptotic adaptations to com-
mon therapies and tested them in combination with BH3
mimetics to achieve a high cytotoxicity, around 80%, while
decreasing ten-fold their concentration, thus their
potential secondary effects. More precisely, we found
novel synergistic combinations of vincristine with the
MCL-1 inhibitor S63845, and doxorubicin with the same
BH3 mimetic or the BCL-xL inhibitor A-1331852 (Fig. 2
and Supplementary Fig. 1); the effectiveness of this last
combination was also observed in osteosarcoma41. These
three new combinations were synergistic as assessed by CI
index (CI < 1) and allowed dosing reduction40. Further-
more, all treatments and combinations with BH3
mimetics reported in this work do not cause cell death
neither in the non-tumoral cell line C2C12 (Supplemen-
tary Fig. 2A) nor in HSMM (Supplementary Fig. 2B),
reinforcing the idea of reducing treatment dosage. These
results strengthen the importance of BCL-xL and MCL-1
as therapeutic targets in pediatric cancer, and specifically
in RMS as it has also been recently reported42. The
described treatments have been explored in multiple adult
cancers23,43, but not in pediatric cancers, where current
treatments present low effectiveness especially in high risk
and relapsed RMS patients40. Previous studies in RMS
also demonstrated that different BH3 mimetics can
potentiate chemotherapeutic treatment effectiveness18,
when combined with an ATP-competitive mTOR inhi-
bitor20 or a histone deacetylase inhibitor12, which sup-
ports exploring these therapies as new approximations to
treat pediatric patients.
As previously mentioned, vincristine is currently used for
RMS treatment40, but we observed that cells acquire resistance
through the anti-apoptotic protein MCL-1. Therefore, we
focused our efforts on testing vincristine effectiveness in
combination with the MCL-1 inhibitor S63845 in vivo. As
PDXs accurately model patients’ outcome26, we used a RMS
PDX model to test the sequential combination of low dose
vincristine therapy with S63845. First, we confirmed using
DBP in PDX-isolated cancer cells that vincristine resistance
was mediated through MCL-1 (Fig. 5b), correlating with our
previous observations in vitro (Fig. 2). When a combination of
vincristine followed by S63845 was sequentially administered,
these PDXs showed a significant reduction on tumor growth
with a tendency to its stabilization (Fig. 5c and Supplementary
Fig. 5 Sequential treatment of vincristine and S63845 stops tumor progression in the PDX model of RMS RMSX1. a DBP results of PDX cells
from RMS cancer patient showing an increase in Δ% priming after vincristine treatment. Results expressed as Δ% priming represents the increase in
priming compared to control cells. n= 2. b DBP results of PDX cells from a RMS cancer patient with the sensitizer peptides. MS1 BH3 peptide showed
a significant increase, indicating MCL-1 adaptation. n= 2. c Tumor growth results after 21 days of treatment with vehicle, vincristine, the BH3
mimetics S63845 and ABT-199 and the combination of vincristine and S63845. Day 0 indicates the day animals received the treatments. All values
indicate mean values ± SEM. **p < 0.01, n= 3.
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Fig. 5C), in accordance with the high cytotoxicity observed
in vitro (Fig. 2b). To further explain this therapeutic strategy
efficacy, we analyzed MCL-1 and NOXA expression but we
could not detect significant changes on those proteins (Fig. 3
and data not shown), pointing to another anti-apoptotic
mechanism driving the acquired resistance to vincristine.
MCL-1 exerts its anti-apoptotic function by sequestering pro-
apoptotic BCL-2 family proteins, such as activators BIM/tBID
or effectors like BAX/BAK, preventing MOMP and avoiding
apoptosis34–36. When analyzing RMS cells, we observed a
significant increase in MCL-1 binding to tBID by co-
immunoprecipitation after vincristine treatment (Fig. 4b).
tBID promotes apoptosis by preferentially binding to the
effector protein BAK35, therefore MCL-1 could decrease
treatment effectiveness. But MCL-1 can also bind to BAK to
protect cells from apoptosis36,37. Interestingly, we could also
observe an increase in MCL-1 binding to BAK after vincristine
treatment which could be reversed by the sequential addition
of S63845 (Fig. 4c). MCL-1 augmented binding to tBID and
BAK explains CW9019 acquired resistance to vincristine and
why the sequential combination of this chemotherapeutic
agent with S63845 restores cytotoxicity both in vitro and
in vivo. Thus, our findings demonstrate that MCL-1 inhibition
after vincristine treatment is critical to allow MOMP and
restore apoptosis in these cells (Fig. 6).
In summary, the work that we here present demon-
strates DBP’s capacity to predict days in advance the
cytotoxic effect of specific treatments in RMS cells. More
interestingly, it can identify how RMS cancer cells acquire
resistance to therapy and new approaches to overcome
dynamic anti-apoptotic adaptations. To our knowledge,
this is the first time that multiple effective sequential
combinations of chemotherapeutics with BH3 mimetics
are reported for RMS in the same study. The specific
capacity of DBP to predict resistance to treatments could
be key to personalize patient’s therapy and to avoid
toxicities derived from ineffective combinations of treat-
ments that do not promote cancer cell death but unde-
sired side effects. We demonstrated in pre-clinical models
(Figs. 2b and 5c) the synergistic antitumor activity of the
MCL-1 inhibitor S63845 when sequentially combined
with vincristine as was previously identified by DBP (Figs.
2a and 5b). Furthermore, this sequential combination will
allow the reduction of chemotherapeutic dosing, which is
essential to decrease the secondary effects derived from
therapy. These findings, together with the current efforts
to target the anti-apoptotic protein MCL-1, currently
explored in clinical trials44, manifest the importance of
rationally combining anti-cancer agents with BH3
mimetics. These novel therapeutic strategies could
improve treatment of RMS patients in the clinic, espe-
cially for those that relapsed, when guided by a functional
predictive biomarker such as DBP.
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